New Findings Could Help Improve Risk Assessment and Treatment
By Melissa Glim
Tuesday, May 10, 2022
Fresh off celebrating Mother’s Day this past Sunday, as well as Women’s Health Week this week, it’s important to acknowledge that being a new mom isn’t easy. As joyful and exciting as a new baby might be, it can be exhausting and worrisome, too. Many new moms experience some level of baby blues, but for some women, those blues can take a downward turn into symptoms of more serious depression.
Approximately one out of every eight women in the U.S. experiences symptoms of postpartum depression, according to the U.S. Centers for Disease Control and Prevention. What’s more, a recent study led by IRP staff scientist Diane Putnick, Ph.D., has shown that the course of postpartum depression can differ significantly among women. The study of nearly 5,000 women not only showed that 25 percent of them experienced symptoms of postpartum depression, but it also found that depression symptoms followed several different patterns and could persist for at least three years after giving birth. Understanding these different patterns of symptoms and some of the risk factors associated with them may help physicians recognize and monitor mothers who are at higher risk for persistent depression.
IRP Researchers Discover Unexpected Stress-Blunting Effects of Some Neurons
By Melissa Glim
Wednesday, April 27, 2022
The past few years have not been easy for anyone. With world events like the COVID-19 pandemic and the war in Ukraine causing everyone to worry, it’s no surprise that during this April’s annual Stress Awareness Month observance, so many people experienced high levels of stress and anxiety. While stress management techniques and talk therapy may help some people, nearly 10 million Americans need prescription anti-anxiety drugs to quell those feelings.
One important target for anti-anxiety medications is norepinephrine, a chemical released by certain neurons in the brain. Norepinephrine — also known as noradrenaline — has traditionally been considered to be a ‘stress chemical’ that triggers anxiety. However, drugs designed to target the neurons that produce it don’t always work as predicted. That’s why IRP senior investigator Patricia Jensen, Ph.D., and her colleagues in the Developmental Neurobiology Group at the National Institute of Environmental Health Sciences (NIEHS) are delving deep into the mouse brain to better understand these neurons and what exactly they do.
Research Suggests Sleep- and Activity-Based Approaches to Treatment
By Melissa Glim
Tuesday, October 5, 2021
Mental Illness Awareness Week, observed this year from October 3 through 9, brings attention and support to the many patients and families who are coping with a variety of psychological conditions. Although an estimated 20 percent of U.S. adults and nearly 17 percent of youth have some type of mental health ailment, these conditions are still not well understood. However, research conducted at the National Institute of Mental Health (NIMH) is transforming our knowledge of one such mental health condition that affects more than two million Americans: bipolar disorder.
Mouse Study Illuminates Potential Mechanism Behind Mood and Anxiety Disorders
By Brandon Levy
Tuesday, July 14, 2020
Millions of Americans suffered from depression and anxiety even before COVID-19 began upending their lives. To make matters worse, the stresses of living through a pandemic might not only worsen mental health but could also wreak havoc on the brain itself. New IRP research has found that psychological stress damages blood vessels in the brains of mice and dramatically alters the behavior of genes in certain blood vessel cells.
5 Questions with Dr. Francis McMahon
By Brooke Worthing
Thursday, October 10, 2019
Depression is one of the most common mental health conditions in the U.S., affecting nearly seven percent of American adults each year. With the increasing social and economic pressures of the modern world likely contributing to depressive symptoms, it is more important now than ever to study depression and the factors that contribute to recovery.
A number of variables contribute to an individual’s overall mental health and response to treatment, including elements of nature and nurture that have long been studied at the NIH. In a 2013 study, researchers led by IRP senior investigator Francis McMahon, M.D., set out to understand the complex genetic factors that he believed might help explain why antidepressants are less effective for African Americans with depression than for other populations. His research revealed that differences in socioeconomics and health explained most of those differences in antidepressant response, and the remaining differences were explained by differences in genetic ancestry, rather than self-reported race. The discovery that genetics play a role in this health disparity could help close the gap and improve depression treatment for African Americans.
By Brandon Levy
Thursday, February 28, 2019
The NIH’s main campus in Bethesda, Maryland, may have the look and feel of a university campus, but the world-renowned research institution does not grant credentials like an M.D. or Ph.D. Instead, the Graduate Partnerships Program offers graduate students from schools around the world the opportunity to complete research for their Ph.D. dissertations in IRP labs while pursuing advanced degrees from their ‘host’ institutions.
By Brandon Levy
Thursday, November 15, 2018
In 2016, more than one in twenty American adults and one in ten adolescents experienced at least one major depressive episode. For nearly 45,000 of these individuals, their condition was severe enough that it led them to take their own lives. Unfortunately, the medications currently available to treat depression are not always effective and can take up to six weeks to substantially reduce symptoms.
To improve treatment and accelerate symptom relief, IRP senior investigator Carlos Zarate Jr., M.D., is working towards the development of new medications for depression, along with the identification of new drug targets and objective measures called biomarkers that yield information about how a patient is responding to treatment. In recent years, his lab has extensively investigated and assessed the effects of the anesthetic drug ketamine on depression and suicidal thoughts. Many of the patients in his trials have had marked and rapid responses to ketamine, sometimes within a single day or just a couple of hours.
On Tuesday, November 13, Dr. Zarate participated in a Reddit “Ask Me Anything” (AMA) to answer questions from the public about the way depression is currently treated and the latest efforts to develop cutting-edge therapies for the condition. Read on for some of the most interesting exchanges that took place or check out the full AMA on Reddit.
By Michele Lyons
Thursday, May 26, 2016
What do Isaac Newton, Thomas Jefferson, Albert Einstein, and Apollo astronauts have in common? They all used slide rules! We're highlighting some of the slide rules in our collection used by scientists at the NIH in their quest to improve human health.
